Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IIITerminatedD-1445-2014

Drug recall · July 30, 2014

Orphenadrine Citrate Extended Release Tablets recall

Why: Failed Dissolution Specifications: Product found to be out of specification (OOS) during stability testing.

Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).

The recall

Product

Orphenadrine Citrate Extended Release Tablets, 100 mg a)100-count bottle, (NDC 0185-0022-01) b) 1000-count bottle, (NDC 0185-0022-10), Rx only, Manufactured by Sandoz Inc., Princeton, NJ 08540.

Lots / codes

Lot # DM1316; Exp. 05/16 Lot # DM1318; Exp. 05/16

Quantity
781,000 extended release tablets
Company
Sandoz Inc, Princeton, NJ
Distribution
Nationwide
Initiated
July 11, 2014 · Voluntary: Firm initiated
Classified
July 23, 2014
Reported
July 30, 2014
Ended
July 10, 2017
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Orphenadrine

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.